Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: Results of two randomized clinical studies

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 2, 2005, Pages 191-197

  Wilder Smith, Clive H ^a   Bondarov, Patrik ^b   Lundgren, Marie ^b   Niazi, Mohammad ^b   Röhss, Kerstin ^b   Ahlbom, Henrik ^b   Nyman, Lars ^c  

^a GI Physiology Laboratory   (Switzerland)

^b ASTRAZENECA R AND D   (Sweden)

^c IQVIA   (United States)

Author keywords

Acid inhibition; Esomeprazole; Gastroesophageal reflux disease; Intravenous; Proton pump inhibitors; Randomized clinical trials

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PH MEASUREMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PH;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 14844330716     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200502000-00010     Document Type: Article

References (18)

1. DiPalma JA. Management of severe gastroesophageal reflux disease. J Clin Gastroenterol 2001; 32:19-26.
2. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172-180.
3. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-2620.
4. Newton M, Kamm MA, Quigley T, Burnham WR. Symptomatic gastroesophageal reflux in acutely hospitalized patients. Dig Dis Sci 1999; 44:140-148.
5. Vinayek R, Frucht H, London JF, Miller LS, Stark HA, Norton PS, et al. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 1990; 99:10-16.
6. Tripathi A, Somwanshi M, Singh B, Bajaj P. A comparison of intravenous ranitidine and omeprazole on gastric volume and pH in women undergoing emergency caesarean section. Can J Anaesth 1995; 42:797-800.
7. Chua RT, Lin HJ, Wang K, Perng CL, Lo WC, Lee CH, et al. Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57:139-145.
8. Geus WP. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol 2000; 232 (Suppl.):10-20.
9. Wilder-Smith C, Röhss K, Bondarov P, Luandin C, Nilsson-Peschl C. Esomeprazole 40 mg administered intravenously (IV) as a 3-minute injection or 30-iminute infusion provides the same effective acid control in healthy subjects [Abstract]. Gastroenterology 2003; 124 (4 Suppl. 1):A-233.
10. Wilder-Smith C, Röhss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole (P) 40 mg [Abstract]. Gastroenterology 2000; 118:A22.
11. Wilder-Smith C, Bondarov P, Hallerbäck B, Nilsson-Pieschl C, Ahlbom H, Röhss K, et al. Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days [Abstract]. Am J Gastroenterol 2003; 98 (9 Suppl.):A-70.
12. Schneider H, Van Rensburg C, Schmidt S. Esomeprazole 40 mg provides safe and effective healing of erosive esophagitis whether administered as an intravenous (IV) injection, an IV infusion, or orally [Abstract]. Am J Gastroenterol 2003; 98 (9 Suppl.):A-31.
13. Röhss K, Bondarov P, Lundin C, Nilsson-Pieschl C, Nyman L, Niazi M. Esomeprazole 40 mg administered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects [Abstract]. Gastroenterology 2003; 122 (4 Suppl. 1):A-231.
14. Wilder-Smith C, Nilsson-Pieschl C, Lundgren M, Ahlbom H, Röhss K. Esomeprazole 20 mg administered as a 30-minute infusion provides a similar level of acid control as oral administration in healthy subjects [Abstract]. Am J Gastroenterol 2003; 98 (9 Suppl):S-21.
15. Wilder-Smith CH, Gennoni MA, Triller J, Scheurer U, Merki HS. Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992; 52:1-5.
16. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28:966-972.
17. Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and i.v. administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56:665-670.
18. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40:411-426.